CORT
CORCEPT THERAPEUTICS INC
NASDAQ · Healthcare · Biotechnology · US
$79.22
−3.31%Year over year
Reported trailing growth
- Revenue
- +30.0%
- EBITDA
- +52.7%
- EBIT
- +69.1%
- EPS
- +50.0%
- Free cash flow
- +19.7%
- Operating cash flow
- +21.7%
Forward estimates
Based on analyst estimates
- Revenue
- +68.5%
- EBITDA
- +365.8%
- EPS
- +199.4%
Three-year CAGR
- Revenue
- +23.7%
- EBITDA
- -17.0%
- EBIT
- -26.5%
- Net income
- -0.6%
- EPS
- +0.0%
- Free cash flow
- +5.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026